Efficacy of voglibose in type 2 diabetes

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 8, 2014, Pages 1181-1190

  Kaku, Kohei ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Impaired glucose tolerance; Postprandial hyperglycemia; Prevention; Type 2 diabetes mellitus; Voglibose

Indexed keywords

ALOGLIPTIN; DAPAGLIFLOZIN; DIGOXIN; GLIBENCLAMIDE; GLUCOSE; HYDROCHLOROTHIAZIDE; INSULIN; LINAGLIPTIN; MITIGLINIDE; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; VOGLIBOSE; WARFARIN; ANTIDIABETIC AGENT; INOSITOL;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADD ON THERAPY; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL PHARMACOLOGY; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; CORONARY ARTERY ATHEROSCLEROSIS; DIABETOGENESIS; DIARRHEA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG INTERACTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMODIALYSIS PATIENT; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; INTESTINE FUNCTION DISORDER; LOSS OF APPETITE; MEDICINAL CHEMISTRY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PNEUMATOSIS INTESTINALIS; RECTUM HEMORRHAGE; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; ATHEROSCLEROSIS; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG COMBINATION; GLUCOSE INTOLERANCE; METABOLISM; PRACTICE GUIDELINE; TREATMENT OUTCOME;

ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG THERAPY, COMBINATION; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; INOSITOL; INSULIN; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84900813593     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.918956     Document Type: Article

References (61)

1. Scheen AJ. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs 2003;63(10):933-51
2. Israili ZH. Advances in the treatment of type 2 diabetes mellitus. Am J Ther 2011;18(2):117-52
3. International Diabetes Federation. 2011 Guideline for management of postmeal glucose in diabetes. International Diabetes Federation, Brussels. 2011. Available from: www.idf.org/sites/default/files/postmeal% 20glucose%20guidelines.pdf [Accessed 25 February 2014]
4. International Diabetes Federation. Diabetes facts and figures. 2013. Available from: www.idf.org/worlddiabetesday/toolkit/gp/facts-figures [Accessed 25 February 2014]
5. Japanese Health Service Bureau of Ministry of Health, Labor and Welfare: 2012 Diabetes Mellitus Survey Report; 2013
6. Choudhary N, Kalra S, Unnikrishnan AG, Ajish TP. Preventive pharmacotherapy in type 2 diabetes mellitus. Indian J Endocrinol Metab 2012;16(1):33-43
7. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161(3):397-405
8. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95, 783 individuals followed for 12.4 years. Diabetes Care 1999;22(2):233-40
9. Ceriello A, Colagiuri S, Gerich J, Tuomilehto J; Guideline Development Group. Guideline for management of postmeal glucose. Nutr Metab Cardiovasc Dis 2008;18(4):S17-33
10. Gavin JR III. Pathophysiologic mechanisms of postprandial hyperglycemia. Am J Cardiol 2001;88(6A):4H-8H
11. Japan Diabetes Society, editor. Evidence-based practice guideline for the treatment of diabetes in Japan, 2013. Nankodo, Tokyo; 2013
12. Standl E, Schnell O. Alpha-glucosidase inhibitors 2012-cardiovascular considerations and trial evaluation. Diab Vasc Dis Res 2012;9(3):163-9
13. Chen X, Zheng Y, Shen Y. Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors. Curr Med Chem 2006;13(1):109-16
14. Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycaemia. Drugs 1999;57(1):19-29
15. Derosa G, Maffioli P. Alpha-glucosidase inhibitors and their use in clinical practice. Arch Med Sci 2012;8(5):899-906
16. Vichayanrat A, Ploybutr S, Tunlakit M, Watanakejorn P. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Diabetes Res Clin Pract 2002;55(2):99-103
17. Abe M, Kikuchi F, Kaizu K, Matsumoto K. Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis. Clin Nephrol 2007;68(5):287-94
18. Abe M, Okada K, Maruyama T, et al. Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis. Expert Opin Pharmacother 2010;11(2):169-76
19. Voglibose dispersible tablets. Summary of Product Characteristics. Available from: www.biocon.com/docs/prescribing-information/diabetology/ volicose-pi.pdf [Accessed 14 February 2014]
20. Fuder H, Kleist P, Birkel M, et al. The alpha-glucosidase inhibitor voglibose (AO-128) does not change pharmacodynamics or pharmacokinetics of warfarin. Eur J Clin Pharmacol 1997;53(2):153-7
21. Kleist P, Suzuki Y, Thomsen T, et al. Voglibose has no effect on the pharmacokinetics of hydrochlorothiazide. Eur J Clin Pharmacol 1998;54(3):273-4
22. Kusumoto M, Ueno K, Fujimura Y, et al. Lack of kinetic interaction between digoxin and voglibose. Eur J Clin Pharmacol 1999;55(1):79-80
23. Kleist P, Ehrlich A, Suzuki Y, et al. Concomitant administration of the alpha-glucosidase inhibitor voglibose (AO-128) does not alter the pharmacokinetics of glibenclamide. Eur J Clin Pharmacol 1997;53(2):149-52
24. Imamura A, Kusunoki M, Ueda S, et al. Impact of voglibose on the pharmacokinetics of dapagliflozin in Japanese patients with type 2 diabetes. Diabetes Ther 2013;4(1):41-9
25. Yamaguchi M, Saji T, Mita S, et al. Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with type 2 diabetes. Int J Clin Pharmacol Ther 2013;51(8):641-51
26. Göke B, Fuder H, Wieckhorst G, et al. Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 1995;56(6):493-501
27. Narita T, Yokoyama H, Yamashita R, et al. Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. Diabetes Obes Metab 2012;14(3):283-7
28. Kageyama S, Nakamichi N, Sekino H, Nakano S. Comparison of the effects of acarbose and voglibose in healthy subjects. Clin Ther 1997;19(4):720-9
29. Matsumoto K, Yano M, Miyake S, et al. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care 1998;21(2):256-60
30. Negishi M, Shimomura K, Proks P, et al. Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in type 2 diabetic patients. Br J Clin Pharmacol 2008;66(2):318-19
31. Satoh N, Shimatsu A, Yamada K, et al. An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. Metabolism 2006;55(6):786-93
32. Shai I, Pischon T, Hu FB, et al. Soluble intercellular adhesion molecules, soluble vascular cell adhesion molecules, and risk of coronary heart disease. Obesity (Silver Spring) 2006;14(11):2099-106
33. Ridker PM, Hennekens CH, Roitman-Johnson B, et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998;351(9096):88-92
34. Seo C, Sakamoto M, Nishimura R, et al. Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study. Diabetes Technol Ther 2013;15(5):378-85
35. Konya H, Katsuno T, Tsunoda T, et al. Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2013;6:317-25
36. Inoue M. Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fixed-dose combination in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother 2012;13(16):2257-68
37. Ono Y, Kameda H, Cho KY. Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother 2013;14(4):361-70
38. Ono Y, Nakamura A, Yong Cho K, Nomoto H. The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and dinner, and effects of the mitiglinide/voglibose fixed-dose combination on postprandial profiles in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother 2014;15(3):311-24
39. Ohta A, Ohshige T, Sakai K, et al. Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-näive Japanese patients with type 2 diabetes. Expert Opin Pharmacother 2013;14(17):2315-22
40. Kurebayashi S, Watada H, Tanaka Y, et al. Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in a crossover study. Endocr J 2006;53(2):213-17
41. Seino Y, Fujita T, Hiroi S, et al. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr Med Res Opin 2011;27(Suppl 3):21-9
42. Seino Y, Fujita T, Hiroi S, et al. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin 2011;27(9):1781-92
43. Kawamori R, Inagaki N, Araki E, et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab 2012;14(4):348-57
44. Iwamoto Y, Tajima N, Kadowaki T, et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab 2010;12(7):613-22
45. Iwamoto Y, Kashiwagi A, Yamada N, et al. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes Metab 2010;12(8):700-8
46. Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009;373(9675):1607-14
47. Kawamori R, Tajima N, Iwamoto Y, et al. Predictive values of serum insulin kinetics for reversion of impaired glucose tolerance to normal glucose tolerance and the effects of voglibose treatment: a retrospective post hoc analysis of a Japanese phase III study. Diabetol Int 2012;3:209-16
48. Lee MY, Choi DS, Lee MK, et al. Comparison of acarbose and voglibose in diabetes patients who are inadequately controlled with basal insulin treatment: randomized, parallel, open-label, active-controlled study. J Korean Med Sci 2014;29(1):90-7
49. Kimura T, Suzuki J, Ichikawa M, et al. Differential effects of a-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50. Diabetes Technol Ther 2012;14(7):545-51
50. Yale JF. Oral antihyperglycemic agents and renal disease: new agents, new concepts. J Am Soc Nephrol 2005;16:7-10
51. Kataoka Y, Yasuda S, Miyamoto Y, et al. Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients. Circ J 2012;76(3):712-20
52. Kataoka Y, Yasuda S, Miyamoto Y, et al. Clinical predictors of atheroma progression despite optimal glycemic control in early-stage diabetic patients with coronary artery disease: insight from the DIANA study. J Atheroscler Thromb 2014. [Epub ahead of print]
53. Emoto T, Sawada T, Hashimoto M, et al. Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease. Am J Cardiol 2012;109(1):42-6
54. Fujitaka K, Otani H, Jo F, et al. Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome. Endocr J 2011;58(6):425-32
55. Tsujimoto T, Shioyama E, Moriya K, et al. Pneumatosis cystoides intestinalis following alpha-glucosidase inhibitor treatment: a case report and review of the literature. World J Gastroenterol 2008;14(39):6087-92
56. Intestinal alpha-glucosidase inhibitors: abdominal gas cysts. Prescrire Int 2012; 21( 130): 212-13
57. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32(1):193-203
58. Shimabukuro M, Masuzaki H, Sata M. Intensive glucose lowering in cardiovascular risk management-unsolved questions. Circ J 2012;76(3):593-5
59. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290(4):486-94
60. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359(9323):2072-7
61. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011;9(3):258-70